Target intelligence / Profile preview

Hepatitis A virus-specific B-cell receptor (HAV-specific BCR)

Target
HAV-specific BCR
Molecular classification
Receptor, Other
01

Overview

Hepatitis A virus-specific B-cell receptors (HAV-specific BCRs) are membrane-bound immunoglobulins expressed on the surface of HAV-specific B lymphocytes. These receptors play a pivotal role in the adaptive immune response by recognizing and binding to specific antigenic epitopes on the capsid of the Hepatitis A virus (HAV). Upon antigen binding, HAV-specific BCRs undergo cross-linking, which initiates intracellular signaling cascades (such as the phosphorylation of CD79a/b and recruitment of Syk kinase) leading to B-cell activation, proliferation, and differentiation into memory B cells and plasma cells that secrete high-affinity neutralizing anti-HAV antibodies. In clinical practice, these receptors are the primary target of inactivated Hepatitis A vaccines (such as Havrix and Vaqta), which mimic natural infection to stimulate the production of protective IgG antibodies. A notable therapeutic challenge associated with these receptors is the potential inhibition of vaccine-induced B-cell activation in infants by maternal antibodies, which can cross-link the BCR with the inhibitory FcγRIIB receptor.

Other names
Hepatitis A virus-specific B-cell receptorsHAV-specific B-cell receptorHAV-specific B-cell receptorsHAV-specific BCRsHepatitis A virus-specific BCR
02

Mechanism of action

Binding of vaccine antigens (inactivated Hepatitis A virus) to the B-cell receptor, inducing receptor cross-linking, intracellular signaling, B-cell activation, clonal expansion, and differentiation into neutralizing antibody-secreting plasma cells and memory B cells.

03

Biological functions

Immune responseSignal transductionCell proliferationOther
04

Disease associations

Infection
05

Safety considerations

Injection site painFeverHeadacheFatigueMaternal antibody interference (inhibiting B-cell activation via FcγRIIB cross-linking)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Anti-HAV IgG antibody titerAnti-HAV IgM antibody titerHAV-specific memory B cell percentage

Beyond the preview

Go deeper on Hepatitis A virus-specific B-cell receptor (HAV-specific BCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis A virus-specific B-cell receptor (HAV-specific BCR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call